Science • Medicine

Novavax vaccine up to 96% effective in UK trial

American vaccine development company Novavax said its Covid-19 vaccine has shown a 96% efficacy against the original Coronavirus strain and a 86% efficacy against the more potent UK strain B117 in Phase 3 clinical trials in the United Kingdom. The vaccine has also shown to be 100% effective against severe Covid-19 infections.

Trials are still running in the United States, and the company will apply for US emergency use authorization as soon as those trials are complete.

Stanley Erck, Novavax's president and CEO, said that the company was "very encouraged by the data".

“We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials. Importantly, both studies confirmed efficacy against the variant strains,” so Erck. “Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19.”

Highly edible human, designer of all things digital, co-founder of Pendect, creative native, constant wa/onderer, morse code lady, full-time dog pillow.
Card reviewed by: @ericof